New guidlines could delay Amylin's long-acting diabetes drug

03/3/2008 | Reuters

The FDA has suggested changes to trials for diabetes drugs, which may delay approval of a once-weekly form of exenatide, a diabetes treatment Amylin Pharmaceuticals is developing with Eli Lilly and Co. and Alkermes. Amylin has already released promising Phase III trial data for the drug's long-acting version but said it does not expect to seek FDA approval before mid-2009.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL